Позикор

Позикор Uses, Dosage, Side Effects, Food Interaction and all others data.

Позикор was withdrawn from the market in 1998 because of potentially harmful interactions with other drugs.

Позикор belongs to a group of medicines called calcium channel blocking agents, or, more commonly, calcium channel blockers. Calcium channel blocking agents affect the movement of calcium into the cells of the heart and blood vessels. As a result, they relax blood vessels and increase the supply of blood and oxygen to the heart while reducing its workload. Позикор is a benzimidazoyl-substituted tetraline that selectively binds and inhibits T-type calcium channels.

Позикор
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Позикор
Availability	Discontinued
Generic	Mibefradil
Mibefradil Other Names	Mibefradil
Related Drugs	amlodipine, aspirin, lisinopril, metoprolol, losartan, furosemide, carvedilol, hydrochlorothiazide, propranolol, atenolol
Type
Formula	C₂₉H₃₈FN₃O₃
Weight	Average: 495.6287 Monoisotopic: 495.289720302
Protein binding	≥ 99%, primarily to alpha 1-acid glycoprotein.
Groups	Investigational, Withdrawn
Therapeutic Class
Manufacturer
Available Country	Russia
Last Updated:	September 19, 2023 at 7:00 am

Uses

For the treatment of angina and high blood pressure.

How Позикор works

Позикор is a tetralol calcium channel blocking agent that inhibits the influx of calcium ions across both the T (low-voltage) and L (high-voltage) calcium channels of cardiac and vascular smooth muscle, with a greater selectivity for T channels. Vasodilation occurs in vascular smooth muscle, causing a decrease in peripheral vascular resistance and a resulting decrease in blood pressure. Позикор causes a slight increase in cardiac output during chronic dosing. Позикор slows sinus and atrioventricular (AV) node conduction, producing a slight reduction in heart rate and a slight increase in the PR interval. It has also been shown to slightly lengthen the corrected sinus node recovery time and AH interval and to raise the Wenckebach point. The mechanism by which mibefradil reduces angina is not known, but is thought to be attributed to a reduction in heart rate, total peripheral resistance (afterload), and the heart rate–systolic blood pressure product at any given level of exercise. The result of these effects is a decrease in cardiac workload and myocardial oxygen demand.

Позикор Alcohol interaction

[Moderate]

Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.

Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.

Caution and close monitoring for development of hypotension is advised during coadministration of these agents.

Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.

Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.

Позикор multivitamins interaction

[Moderate] Calcium-containing products may decrease the effectiveness of calcium channel blockers by saturating calcium channels with calcium.

Calcium chloride has been used to manage acute severe verapamil toxicity.

Management consists of monitoring the effectiveness of calcium channel blocker therapy during coadministration with calcium products.

Позикор Drug Interaction

Major: fluticasone / salmeterol, fluticasone / salmeterol, fluticasone, fluticasoneModerate: aripiprazole, aripiprazole, acetaminophen / codeine, acetaminophen / codeine, dutasteride, dutasteride, digoxin, digoxinUnknown: aspirin / dipyridamole, aspirin / dipyridamole, celecoxib, celecoxib, rosuvastatin, rosuvastatin, potassium chloride, potassium chloride

Elimination Route

Bioavailability after a single dose is 70%. After multiple dosing, the proportion of mibefradil undergoing first-pass metabolism is reduced, resulting in a steady state bioavailability of approximately 90%. Food does not affect the rate or extent of absorption of mibefradil.